March 11, 2008

From the News Wire - Merck and Marcadia

Indianapolis startup Marcadia Biotech Inc. announced it has signed an agreement with drug giant Merck & Co. Inc. to help bring Marcadia’s promising diabetes therapies to market.

So what?

I never heard of them either.

Well they are trying for a more stable glucagon. News but not earth shattering. We had a few glucagon kits just in case but have never used one. YDMV

The company’s first product in development will address hypoglycemia, or low blood sugar. Severe hypoglycemia is most common in people with diabetes and occurs when there is not enough glucose, or sugar, in the blood to maintain the body’s energy level. Normally the body responds to low blood sugar by releasing the hormone glucagon, which triggers a sequence of events to restore blood sugar levels to normal. In people with impaired endocrine systems, this normal response does not occur. It may be possible to treat hypoglycemia by taking glucose tablets or by eating food or candy. In other cases that are more severe, glucagon is injected to restore adequate glucose levels.

Marcadia Biotech is developing an innovative and novel solution: glucagon that is stable in solution, enabling delivery via an injector pen. This will provide a product that is ready for immediate use in an emergency situation – no mixing will be required.